Safety Profile Overview
Long-acting injectable aripiprazole for schizophrenia maintenance. Monitored for injection site reactions and akathisia.
Generic Name
aripiprazole
Brand Names
Abilify Maintena
Therapeutic Class
Atypical Antipsychotic LAI
Manufacturer
Otsuka
What Pharma Signal Tracks for Abilify Maintena
- Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Abilify Maintena, including serious outcomes, hospitalizations, and deaths.
- FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Abilify Maintena products.
- Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
- Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
- Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
- Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.
Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.
Get Abilify Maintena Safety Data via API
One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Abilify Maintena.
curl "https://api.pharma-signal.com/drug/safety/abilify-maintena" \ -H "X-API-Key: your_key" # Returns risk score, adverse event counts, # serious/death rates, recalls, and signals
Related Safety Intelligence
Pharma Signal provides comparative analysis across therapeutic classes. Compare Abilify Maintena against other Atypical Antipsychotic LAI drugs, or explore the full manufacturer portfolio for Otsuka.
- Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
- Therapeutic class benchmarking — See how Abilify Maintena ranks within Atypical Antipsychotic LAI on serious event rates.
- Company portfolio risk — View all drugs from Otsuka with aggregate risk exposure.
- AI analyst briefs — Get a natural-language safety assessment combining all data sources.